Status:
NOT_YET_RECRUITING
Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
Lead Sponsor:
Mayo Clinic
Conditions:
Ewing Sarcoma
Round Cell Sarcoma With EWSR1-non-ETS Fusion
Eligibility:
All Genders
2+ years
Phase:
NA
Brief Summary
This clinical trial evaluates the effect of radiotherapy doses based on tumor size and tumor-specific characteristics (biologically-adapted) in treating patients with Ewing sarcoma. Radiotherapy uses ...
Eligibility Criteria
Inclusion
- PRE-REGISTRATION: INCLUSION CRITERIA
- Histological confirmation of Ewing sarcoma, including both skeletal and extra-skeletal primary tumors. Patients with "Ewing-like" sarcoma may be eligible if patients are planned to be treated per Ewing treatment paradigms, as defined in this clinical trial REGISTRATION: INCLUSION CRITERIA
- Patients of age ≥ 2 years are eligible for the study
- Lansky or Karnofsky performance status ≥ 70
- Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance
- Willing to provide blood samples for correlative research purposes
- COHORT A ONLY: Willing to provide biopsy sample to run Mayo Complete Solid Tumor Panel
Exclusion
- REGISTRATION: EXCLUSION CRITERIA
- Prior chemotherapy or radiotherapy that, in the opinion of the treating medical oncologist or radiation oncologist, is considered to interfere with the current treatment or measurement of outcomes
- Receiving any investigational agent which would be considered as a treatment for the primary neoplasm that is considered by the investigator to interfere with the current treatment or measurement of outcomes
- Note: Co-enrollment on another clinical trial is allowed per the treating radiation oncologist's discretion
- Other active malignancy ≤ 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes
- Patients that have severe co-morbid systemic illness or other disease which would interfere significantly with the current treatment or measurement of outcomes
- Patients that have active uncontrolled systemic infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness or social situation that would limit study adherence
- Any of the following:
- Pregnant patients
- Nursing patients
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
141 Patients enrolled
Trial Details
Trial ID
NCT07188532
Start Date
December 1 2025
End Date
December 31 2029
Last Update
October 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905